Tonix Pharmaceuticals Holding Corp.（TNXP）旗下药物Tonmya在关键性三期RESILIENT临床试验中取得突破性成果。研究数据显示，与安慰剂组相比，Tonmya治疗组在纤维肌痛患者疼痛症状改善方面表现出统计学意义的显著优势。
该结果标志着纤维肌痛治疗领域的重要进展，为Tonix Pharmaceuticals后续向监管机构提交新药申请奠定了坚实基础。公司表示将继续推进相关数据分析工作，并积极筹备后续申报流程。
Tonix Pharmaceuticals Holding Corp.（TNXP）旗下药物Tonmya在关键性三期RESILIENT临床试验中取得突破性成果。研究数据显示，与安慰剂组相比，Tonmya治疗组在纤维肌痛患者疼痛症状改善方面表现出统计学意义的显著优势。
该结果标志着纤维肌痛治疗领域的重要进展，为Tonix Pharmaceuticals后续向监管机构提交新药申请奠定了坚实基础。公司表示将继续推进相关数据分析工作，并积极筹备后续申报流程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.